(S (NP (NN Prostate) (NN cancer) (PRN (-LRB- -LRB-) (NP (NN PCa)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN cancer)) (PP (IN in) (NP (NP (NNS men)) (PP (IN in) (NP (DT the) (NNP United) (NNP States))))))) (. .))
(S (NP (JJ Multiparametic) (NML (NML (JJ magnetic) (NN resonance)) (NN imaging) (PRN (-LRB- -LRB-) (NP (NN mp) (HYPH -) (NN MRI)) (-RRB- -RRB-)))) (VP (VBZ has) (VP (VBN been) (VP (VBN explored) (PP (IN by) (NP (JJ many) (NNS researchers))) (PP (IN to) (NP (NP (VBN targeted) (NN prostate) (NNS biopsies)) (CC and) (NP (NN radiation) (NN therapy))))))) (. .))
(S (ADVP (RB However)) (PRN (, ,) (S (NP (NP (NN assessment)) (PP (IN on) (NP (NN mp) (HYPH -) (NN MRI)))) (VP (MD can) (VP (VB be) (ADJP (JJ subjective))))) (, ,)) (NP (NP (NN development)) (PP (IN of) (NP (NP (ADJP (NN computer) (HYPH -) (VBN aided)) (NN diagnosis) (NNS systems)) (S (VP (TO to) (ADVP (RB automatically)) (VP (VB delineate) (NP (NP (DT the) (NN prostate) (NN gland)) (CC and) (NP (NP (DT the) (JJ intraprostratic) (NNS lesions)) (-LRB- -LRB-) (NP (NNS ILs)) (-RRB- -RRB-))))))))) (VP (VBZ becomes) (ADJP (JJ important) (S (VP (TO to) (VP (VB facilitate) (PP (IN with) (NP (NP (NNS radiologists)) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (ADVP (RB first)) (VP (VB study) (NP (NP (DT the) (NN implementation)) (PP (IN of) (NP (DT the) (NML (NN Mask) (HYPH -) (NN RCNN)) (NN model)))) (PP (IN to) (NP (NP (NN segment)) (NP (DT the) (NN prostate) (CC and) (NNS ILs))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD trained)) (CC and) (VP (VBD evaluated) (NP (NNS models)) (PP (IN on) (NP (CD 120) (NNS patients))) (PP (IN from) (NP (NP (CD two) (JJ different) (NNS cohorts)) (PP (IN of) (NP (NNS patients))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VP (VBD used) (NP (NML (NN 2D) (NN U-Net) (CC and) (NN 3D)) (NN U-Net)) (PP (IN as) (NP (NNS benchmarks))) (PP (IN to) (NP (NP (NN segment)) (NP (DT the) (NN prostate))))) (CC and) (VP (VBN compared) (NP (NP (DT the) (NN model) (POS 's)) (NN performance)))) (. .))
(S (NP (NP (DT The) (NN contour) (NN variability)) (PP (IN of) (NP (NP (NNS ILs)) (VP (VBG using) (NP (DT the) (NN algorithm)))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN benchmarked) (PP (IN against) (NP (NP (DT the) (NN interobserver) (NN variability)) (PP (IN between) (NP (NP (CD two) (JJ different) (NN radiation) (NNS oncologists)) (PP (IN on) (NP (CD 19) (NNS patients))))))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NML (NN Mask) (HYPH -) (NN RCNN)) (NN model)) (VP (VP (VBZ is) (ADJP (JJ able) (S (VP (TO to) (VP (VB reach) (NP (NML (NML (NN state)) (HYPH -) (PP (IN of) (HYPH -) (NP (NN art)))) (NN performance)) (PP (IN in) (NP (DT the) (NN prostate) (NN segmentation)))))))) (CC and) (VP (VBZ outperforms) (NP (JJ several) (JJ competitive) (NNS baselines)) (PP (IN in) (NP (NN ILs) (NN segmentation)))))))) (. .))
